首页> 美国卫生研究院文献>Journal of Hematology >Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma
【2h】

Concurrent Presentation of Hairy Cell Leukemia and Mantle Cell Lymphoma (Leukemic Non-Nodal Variant): An Extremely Rare Composite Lymphoma

机译:毛细胞白血病和套细胞淋巴瘤(白血病非结节变异)并发表现:一种极其罕见的复合淋巴瘤

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Herein, we describe the clinicopathologic and genetic characteristics of the first report of simultaneous bone marrow involvement by classical hairy cell leukemia (HCL) and leukemic non-nodal variant of mantle cell lymphoma (L-NN-MCL) with t(11;14)(q13;q32) with BRAF mutation and deletion of TP53. A 40-year-old asymptomatic man was investigated for incidental neutropenia and thrombocytopenia. Flow cytometry showed two distinct monotypic B-cell populations: one expressed CD19 (bright), CD20 (bright), FMC7, CD103, CD25, CD11c, CD123, and IgD (bright) and showed kappa light chain restriction (bright), consistent with HCL and the other kappa-restricted CD5/CD10-negative B-cell population with distinctive immunophenotypic features. The bone marrow biopsy is infiltrated by an abnormal B-lymphoid infiltrate with different patterns of infiltration in different marrow areas. Fluorescence in situ hybridization (FISH) analysis revealed a CCND1/IGH rearrangement, t(11;14)(q13;q32), and deletion of TP53. The BRAF V600E missense mutation was detected by quantitative real-time polymerase chain reaction (PCR). The diagnosis of a composite B-cell neoplasm was composed of HCL together with a second CD5/CD10-negative monotypic B-cell population, with CCND1/IGH fusion, favoring the 2016 WHO new category of L-NN-MCL (CD5/SOX11-negative). Treatment with cladribine and rituximab normalized the blood counts within 6 weeks without significant side effects. L-NN-MCL is one of the smoldering MCL subtypes, recently listed in WHO 2016 as a separate variant, with a particular set of unique features and a less aggressive clinical course compared to classical MCL. To date, the clinicopathological features (including the bone marrow findings) of L-NN-MCL have not been sufficiently characterized in the literature. We describe the first report of synchronous presentation of HCL and L-NN-MCL. This case represents a real challenge from the biologic, diagnostic and therapeutic point of views, due to extremely rare combination of two distinct uncommon B-cell neoplasms. The study of composite lymphomas offers the opportunity to evaluate the etiology and the clonal interrelationship involved in the pathogenesis/evolution of lymphomas.
机译:在此,我们描述了经典毛细胞白血病 (HCL) 和套细胞淋巴瘤白血病非淋巴结变体 (L-NN-MCL) 同时累及骨髓的临床病理学和遗传学特征 t(11;14)(q13;q32) 具有 BRAF 突变和 TP53 缺失。一名 40 岁无症状男性接受了偶发性中性粒细胞减少和血小板减少症的调查。流式细胞术显示两个不同的单型 B 细胞群:一个表达 CD19 (明亮)、CD20 (明亮)、FMC7、CD103、CD25、CD11c、CD123 和 IgD (明亮),并显示 κ 轻链限制(明亮),与 HCL 和另一个 κ 限制性 CD5/CD10 阴性 B 细胞群一致,具有独特的免疫表型特征。骨髓活检由异常的 B 淋巴浸润浸润,在不同骨髓区域具有不同的浸润模式。荧光原位杂交 (FISH) 分析显示 CCND1/IGH 重排 t(11;14)(q13;q32) 和 TP53 缺失。通过实时定量聚合酶链反应 (PCR) 检测 BRAF V600E 错义突变。复合 B 细胞肿瘤的诊断由 HCL 和第二个 CD5/CD10 阴性单型 B 细胞群组成,具有 CCND1/IGH 融合,有利于 2016 年 WHO 新类别的 L-NN-MCL (CD5/SOX11 阴性)。克拉屈滨和利妥昔单抗治疗在 6 周内使血细胞计数正常,无明显副作用。L-NN-MCL 是阴燃型 MCL 亚型之一,最近在 WHO 2016 中被列为单独的变体,与传统 MCL 相比,具有一组特定的独特特征和侵袭性较低的临床病程。迄今为止,L-NN-MCL 的临床病理特征 (包括骨髓发现) 在文献中尚未得到充分表征。我们描述了 HCL 和 L-NN-MCL 同步表现的首次报告。从生物学、诊断和治疗的角度来看,这个病例代表了一个真正的挑战,因为两种不同的不常见的 B 细胞肿瘤的组合极其罕见。复合淋巴瘤的研究为评估淋巴瘤发病机制/演变中涉及的病因和克隆相互关系提供了机会。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号